No­vo to buy mid-stage heart fail­ure biotech Car­dior for up to $1.1B

No­vo Nordisk plans to ac­quire Ger­man biotech Car­dior Phar­ma­ceu­ti­cals, a Phase 2 RNA start­up, for up to $1.1 bil­lion to boost its pres­ence in car­dio­vas­cu­lar dis­ease, the Dan­ish drug gi­ant said Mon­day morn­ing.

The move comes three weeks af­ter No­vo’s obe­si­ty drug We­govy re­ceived a la­bel ex­pan­sion to in­clude the re­duc­tion of car­dio­vas­cu­lar events, an ap­proval that could open the doors to more cov­er­age. Last year, No­vo’s ac­qui­si­tions were fo­cused on obe­si­ty, with a $1.075 bil­lion deal for In­ver­sa­go and Em­bark Biotech for about $500 mil­lion to­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER